Scope Fluidics begins preparations for the accelerated registration procedure of the PCR|ONE SARS-CoV-2 panel in the USA
Curiosity Diagnostics, owned by Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects, signed an agreement with Prof. Krzysztof Pyrc, PhD, with the participation …
Curiosity Diagnostics obtains ISO 13485:2016 certification
Curiosity Diagnostics, owned by Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects, following an audit conducted by an independent body, received a certificate …
Subsidiary of Scope Fluidics receives a positive recommendation for certification in accordance with ISO 13485:2016
Curiosity Diagnostics, owned by Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has successfully passed an ISO 13485 certification audit, which proved …
Scope Fluidics obtains patent protection for the PCR|ONE technology in China
Curiosity Diagnostics, owned by Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects, obtained a Chinese patent which protects the key technology of the …
Scope Fluidics has developed an ultra-fast PCR|ONE genetic test for coronavirus
Curiosity Diagnostics, owned by Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects
PCR|ONE is ready for the final stage on the way to registering the ultra-fast, genetic diagnostic panel
Curiosity Diagnostics – member of the Scope Fluidics S.A. Group – has completed the fifth stage of works on the PCR|ONE molecular diagnostics system on time. This means that the …
Scope Fluidics is developing an Ultra-Fast COVID-19 Panel for its PCR|ONE Rapid Molecular Diagnostic System
The Management Board of Scope Fluidics SA has decided to extend the work on a panel for detecting viral respiratory tract infections by developing an ultra-fast test for detecting the …
Presentation of the PCR|ONE system at the MedLab Middle East conference in Dubai
The PCR|ONE system, developed by Scope Fluidics, a New Connect-listed company, has gained great interest from market representatives and journalists during one of the largest medical diagnostics conferences in the …
Scope Fluidics has launched a manufacturing line for PCR system chips
Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has launched its own semi-automatic manufacturing line in Warsaw, which allows for independent production …
The PCR|ONE system developed by Scope Fluidics achieves standard market parameters –the outcome of the second round of research in ALAB laboratories is now available
Curiosity Diagnostics – a member of the Scope Fluidics S.A. Capital Group – successfully completed the second series of pre-validation tests of the PCR|ONE system in ALAB laboratories. The results …
Scope Fluidics patents the key solution of the PCR|ONE system in the European Patent Office
Curiosity Diagnostics – a company that belongs to the Scope Fluidics S.A. Capital Group – has announced that it has obtained a conditional decision from the European Patent Office on …
Scope Fluidics has completed the fourth stage of the PCR|ONE system – the panel for detecting Staphylococcus aureus is ready for testing in ALAB laboratoria
Curiosity Diagnostics, a company belonging to the Scope Fluidics S.A. Capital Group, has completed the fourth stage of R&D works on the PCR|ONE system for automatic analysis of the genetic …
Two Scope Fluidics projects among the most ground-breaking diagnostic products in the American Association for Clinical Chemistry competition
PCR|ONE and BacterOMIC, two innovative medical diagnostic systems developed by Scope Fluidics, a biotechnology company listed on NewConnect, are among the seven breakthrough medical solutions from around the world competing …
Materials to download
Teaser PCR ONE
Events
Medica Trade Fair
Dusseldorf | 18-21 November 2019
MedLab Middle East Congress
Dubai | 8-11 February 2020
The fastest access to molecular Dx information
15
min
rapid test results
20
genes
targets in a single test
64
PCR
reactions in a single test